-
ENA Respiratory Begins Part B Dosing in INNA-051 Phase IIa Community Study Designed to Protect Against Symptomatic Viral Respiratory Infections
MELBOURNE, Australia, Sept. 15, 2026 (GLOBE NEWSWIRE) — ENA Respiratory, a clinical-stage pharmaceutical company
Lifestyle Content
Technology
-
DJ / Producer LxAM Connects Canada and Miami With ‘I Just Wanna Dance’
-
Skiter Weez and Dalo Join Zaeskee Alazae for a New Midwest Music Movement
-
R&B/Pop Singer The First Lady OLIVIA Commands Her Narrative with Her New Single, ‘VENOM’
-
OpenArt Director Ranks No. 1 in Anime on Physion Labs’ ARC 1.0 AI Video Agent Benchmark
-
Masha Kova Turns Up the Heat With New Single “Red Light Green Light”
Entertainment
-
NooCube Reviews: Announces U.S. Availability of Nootropic for Brain Productivity Supplement
-
Lawsuit Alleges American Deli Food Caused Severe Illness, Acute Kidney Failure, And Eight-day Hospitalization
-
New Jersey Pediatric Neuroscience Institute Expands Into Multiple Integrated Specialties, Building One of the State’s Most Comprehensive Pediatric Brain and Nervous System Practices
-
Hera Fertility Connects Men Directly with Certified Labs for Faster Male Fertility Testing
-
European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP
